"Bile Acids and Salts" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Steroid acids and salts. The primary bile acids are derived from cholesterol in the liver and usually conjugated with glycine or taurine. The secondary bile acids are further modified by bacteria in the intestine. They play an important role in the digestion and absorption of fat. They have also been used pharmacologically, especially in the treatment of gallstones.
| Descriptor ID |
D001647
|
| MeSH Number(s) |
D04.210.500.105
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Bile Acids and Salts".
Below are MeSH descriptors whose meaning is more specific than "Bile Acids and Salts".
This graph shows the total number of publications written about "Bile Acids and Salts" by people in this website by year, and whether "Bile Acids and Salts" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 3 | 3 |
| 1998 | 3 | 0 | 3 |
| 1999 | 1 | 0 | 1 |
| 2000 | 3 | 1 | 4 |
| 2001 | 3 | 0 | 3 |
| 2002 | 2 | 0 | 2 |
| 2003 | 5 | 1 | 6 |
| 2004 | 1 | 0 | 1 |
| 2005 | 2 | 2 | 4 |
| 2006 | 1 | 0 | 1 |
| 2007 | 1 | 2 | 3 |
| 2008 | 2 | 1 | 3 |
| 2009 | 3 | 1 | 4 |
| 2010 | 5 | 2 | 7 |
| 2011 | 0 | 2 | 2 |
| 2012 | 1 | 1 | 2 |
| 2013 | 7 | 1 | 8 |
| 2014 | 1 | 3 | 4 |
| 2015 | 6 | 1 | 7 |
| 2016 | 3 | 3 | 6 |
| 2017 | 0 | 1 | 1 |
| 2018 | 1 | 1 | 2 |
| 2019 | 7 | 1 | 8 |
| 2020 | 5 | 2 | 7 |
| 2021 | 7 | 3 | 10 |
| 2022 | 6 | 5 | 11 |
| 2023 | 1 | 8 | 9 |
| 2024 | 3 | 4 | 7 |
| 2025 | 8 | 4 | 12 |
| 2026 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Bile Acids and Salts" by people in Profiles.
-
Constitutive AMPK activation prevents hepatocellular carcinoma development through inhibition of HNF4a activity. Sci Adv. 2026 Apr 10; 12(15):eaea8017.
-
Myosin 5b deficiency alters liver proliferation, zonation, and bile acid composition. Hepatol Commun. 2026 Mar 01; 10(3).
-
Beyond bile acids synthesis: metabolomics profiling highlights extensive metabolic dysregulation and treatment response in CTX. Orphanet J Rare Dis. 2026 Jan 30; 21(1).
-
A Randomized Phase 1 Study Investigating Gut Microbiome Changes With Moxifloxacin vs Oral Vancomycin: Implications for Clostridioides difficile Risk. J Infect Dis. 2025 Dec 20; 232(6):1446-1456.
-
Faecal pharmacokinetics, microbiome, and bile acid changes in healthy subjects given intravenous followed by oral omadacycline; a Phase 1 clinical trial. J Antimicrob Chemother. 2025 Oct 03; 80(10):2719-2726.
-
Selective agonism of liver and gut FXR prevents cholestasis and intestinal atrophy in parenterally fed neonatal pigs. J Lipid Res. 2025 Nov; 66(11):100919.
-
Inhibition of SREBP-1c rescues hepatic CYP7B1 expression and bile acid synthesis in malnourished mice. Am J Physiol Gastrointest Liver Physiol. 2025 07 01; 329(1):G232-G243.
-
Changes in the FXR-cistrome and alterations in bile acid physiology in Wilson disease. Hepatol Commun. 2025 Jun 01; 9(6).
-
Bile acid regulation of xenobiotic nuclear receptors on the expressions of orosomucoids in the liver. Am J Physiol Endocrinol Metab. 2025 06 01; 328(6):E940-E951.
-
Multicomponent parenteral lipid emulsions do not prevent liver injury in neonatal pigs with obstructive cholestasis. JCI Insight. 2025 May 22; 10(10).